HomeCompareISBC vs ABBV

ISBC vs ABBV: Dividend Comparison 2026

ISBC yields 21.83% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ISBC wins by $116771762.53M in total portfolio value
10 years
ISBC
ISBC
● Live price
21.83%
Share price
$13.87
Annual div
$3.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$116771762.63M
Annual income
$115,752,943,300,661.28
Full ISBC calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ISBC vs ABBV

📍 ISBC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodISBCABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ISBC + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ISBC pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ISBC
Annual income on $10K today (after 15% tax)
$1,855.20/yr
After 10yr DRIP, annual income (after tax)
$98,390,001,805,562.10/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ISBC beats the other by $98,390,001,784,506.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ISBC + ABBV for your $10,000?

ISBC: 50%ABBV: 50%
100% ABBV50/50100% ISBC
Portfolio after 10yr
$58385881.37M
Annual income
$57,876,471,662,716.52/yr
Blended yield
99.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ISBC
Analyst Ratings
10
Buy
8
Hold
Consensus: Buy
Altman Z
0.9
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ISBC buys
0
ABBV buys
0
No recent congressional trades found for ISBC or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricISBCABBV
Forward yield21.83%3.06%
Annual dividend / share$3.03$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$116771762.63M$102.3K
Annual income after 10y$115,752,943,300,661.28$24,771.77
Total dividends collected$116704072.98M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: ISBC vs ABBV ($10,000, DRIP)

YearISBC PortfolioISBC Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$15,065$4,365.19$11,550$430.00+$3.5KISBC
2$28,412$12,292.02$13,472$627.96+$14.9KISBC
3$73,731$43,330.47$15,906$926.08+$57.8KISBC
4$289,072$210,180.23$19,071$1,382.55+$270.0KISBC
5$1,849,568$1,540,260.93$23,302$2,095.81+$1.83MISBC
6$20,399,656$18,420,617.67$29,150$3,237.93+$20.37MISBC
7$401,582,049$379,754,416.90$37,536$5,121.41+$401.54MISBC
8$14,403,041,597$13,973,348,804.96$50,079$8,338.38+$14402.99MISBC
9$952,167,596,512$936,756,342,002.87$69,753$14,065.80+$952167.53MISBC
10$116,771,762,628,929$115,752,943,300,661.28$102,337$24,771.77+$116771762.53MISBC

ISBC vs ABBV: Complete Analysis 2026

ISBCStock

Investors Bancorp, Inc. operates as the bank holding company for Investors Bank that provides various banking products and services to individuals and businesses in the United States. Its deposit products include savings, checking, and money market accounts. The company's loan portfolio comprises multi-family, commercial real estate, commercial and industrial, and construction loans; one-to four-family residential mortgage loans secured by one-to four-family residential real estate; and consumer and other loans primarily consisting of home equity loans, and home equity lines of credit, as well as various life insurance products. As of December 31, 2021, it operated through a network of 154 branches in New Jersey, New York, and Pennsylvania. Investors Bancorp, Inc. was founded in 1926 and is headquartered in Short Hills, New Jersey.

Full ISBC Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ISBC vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ISBC vs SCHDISBC vs JEPIISBC vs OISBC vs KOISBC vs MAINISBC vs JNJISBC vs MRKISBC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.